{"id":"topiramate-monotherapy","safety":{"commonSideEffects":[{"rate":"10-15%","effect":"Cognitive impairment / memory problems"},{"rate":"15-20%","effect":"Paresthesia"},{"rate":"5-10%","effect":"Weight loss"},{"rate":"10-15%","effect":"Fatigue"},{"rate":"10-15%","effect":"Dizziness"},{"rate":"<1%","effect":"Acute myopia / angle-closure glaucoma"},{"rate":"1-5%","effect":"Metabolic acidosis"}]},"_chembl":{"chemblId":"CHEMBL220492","moleculeType":"Small molecule","molecularWeight":"339.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Topiramate potentiates the activity of the inhibitory neurotransmitter GABA at GABA-A receptors, thereby increasing neuronal inhibition. Additionally, it blocks voltage-gated sodium channels, which reduces repetitive neuronal firing. These dual mechanisms make it effective for seizure control and other neurological conditions.","oneSentence":"Topiramate is an anticonvulsant that enhances GABA-mediated inhibition and blocks sodium channels to reduce neuronal excitability.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:13:19.272Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy / seizure disorders (monotherapy and adjunctive therapy)"},{"name":"Migraine prophylaxis"},{"name":"Essential tremor"}]},"trialDetails":[{"nctId":"NCT07413731","phase":"","title":"Neurophysiological Effects of Medication Tapering During Treatment With Spinal Cord Stimulation","status":"RECRUITING","sponsor":"Brai²n","startDate":"2025-02-03","conditions":"Persistent Spinal Pain Syndrome Type 2 (PSPS-T2), Lower Spine, Spinal Cord Sensitivity to Neurostimulation, Neurophysiological Sensitivity to Spinal Cord Stimulation","enrollment":50},{"nctId":"NCT03689114","phase":"PHASE4","title":"Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-05-10","conditions":"Epilepsies, Partial","enrollment":58},{"nctId":"NCT02201251","phase":"PHASE3","title":"A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-10-06","conditions":"Epilepsy","enrollment":63},{"nctId":"NCT01689649","phase":"PHASE4","title":"A Study to Assess Tolerability and Efficacy of Topiramate Monotherapy in Recently Diagnosed Patients With Epilepsy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2008-05-02","conditions":"Epilepsy","enrollment":139},{"nctId":"NCT05759845","phase":"PHASE4","title":"Topiramate, Amitriptyline Monotherapy and Combination Therapy in Migraine Prophylaxis","status":"UNKNOWN","sponsor":"Dr. Reaz Mahmud","startDate":"2022-08-22","conditions":"Migraine","enrollment":150},{"nctId":"NCT05236166","phase":"NA","title":"Multicentre Study on Rapid Versus Slow Withdrawal of Antiepileptic Monotherapy","status":"COMPLETED","sponsor":"University Magna Graecia","startDate":"2017-04-26","conditions":"Epilepsy","enrollment":48},{"nctId":"NCT01627860","phase":"PHASE4","title":"First Add-on vs. Mono-therapy Study of Topiramate in Neuro-Surgical Patients","status":"COMPLETED","sponsor":"Johnson & Johnson Taiwan Ltd","startDate":"2010-02","conditions":"Epilepsy","enrollment":55},{"nctId":"NCT01030094","phase":"","title":"A Cross-sectional Study to Investigate the Effect of Topiramate on Bone and Mineral Metabolism in Female Participants With Epilepsy","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2007-02","conditions":"Seizures, Convulsions, Epilepsy","enrollment":140},{"nctId":"NCT00210782","phase":"PHASE3","title":"A Comparison of the Effectiveness and Safety of Topiramate and Phenytoin in Patients With New Onset Epilepsy Requiring Rapid Initiation of Antiepileptic Drug Treatment","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-06","conditions":"Epilepsy","enrollment":262},{"nctId":"NCT00266604","phase":"PHASE4","title":"A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2005-12","conditions":"Epilepsy, Seizures, Epilepsies, Partial","enrollment":409},{"nctId":"NCT00986336","phase":"PHASE1","title":"A Pharmacokinetic Study of Risperidone and Topiramate Administered Alone and in Combination in Patients With Bipolar Disorder or Schizoaffective Disorders","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2001-02","conditions":"Bipolar Disorder","enrollment":56},{"nctId":"NCT00266591","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Topiramate Treatment in Patients With Epilepsy","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1992-10","conditions":"Epilepsy, Seizures","enrollment":51},{"nctId":"NCT00231556","phase":"PHASE3","title":"A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent Epilepsy","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1999-07","conditions":"Epilepsy, Seizures, Epilepsies, Partial","enrollment":750},{"nctId":"NCT00236717","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With Epilepsy","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1997-09","conditions":"Epilepsy, Seizures","enrollment":865},{"nctId":"NCT00230698","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Topiramate Monotherapy in Patients With Recently Diagnosed Partial-Onset Seizure","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1995-11","conditions":"Epilepsy, Epilepsies, Partial, Seizures","enrollment":451},{"nctId":"NCT00297323","phase":"","title":"An Observational Study of the Safety of Topiramate in Adults and Children With Epilepsy","status":"COMPLETED","sponsor":"Janssen Cilag Pharmaceutica S.A.C.I., Greece","startDate":"2005-06","conditions":"Seizures, Epileptic","enrollment":80},{"nctId":"NCT00154076","phase":"PHASE4","title":"A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies","status":"COMPLETED","sponsor":"Eisai Korea Inc.","startDate":"2005-09","conditions":"Epilepsy","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":83,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Topiramate monotherapy","genericName":"Topiramate monotherapy","companyName":"Johnson & Johnson Taiwan Ltd","companyId":"johnson-johnson-taiwan-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Topiramate is an anticonvulsant that enhances GABA-mediated inhibition and blocks sodium channels to reduce neuronal excitability. Used for Epilepsy / seizure disorders (monotherapy and adjunctive therapy), Migraine prophylaxis, Essential tremor.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}